After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The US Food and Drug Administration recently approved a new treatment option for patients with relapsed or refractory acute myeloid leukemia who have IDH2 mutations.
To address growing public health concerns, the US Food and Drug Administration is designing a new plan to serve as a roadmap for regulating tobacco products in the future, in order to reduce smoking...
To address growing public health concerns, the US Food and Drug Administration is designing a new plan to serve as a roadmap for regulating tobacco products in the future, in order to reduce smoking...
The FDA has expanded the approval of an intravenous injection for the treatment of metastatic or unresectable melanoma to include use in pediatric patients.
